Analysts Mixed As Australia’s CSL Moves To Settle U.S. Price Fixing Case
This article was originally published in PharmAsia News
Executive Summary
Australia’s CSL has probably made the right decision to settle a price-fixing lawsuit in the United States and thereby avoid a protracted legal battle that could have seen further substantial legal costs even if it eventually won. But the proposed settlement has some analysts concerned the legal basis for the lawsuit was thin as it stemmed from regulatory questions raised in a failed industry merger.